Semin Reprod Med 2003; 21(3): 301-308
DOI: 10.1055/s-2003-43308
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Polycystic Ovary Syndrome in Adolescence

Deborah A. Driscoll
  • Division of Reproductive Genetics, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
31 October 2003 (online)

ABSTRACT

Polycystic ovary syndrome (PCOS) is a relatively common disorder among adolescent women. The typical clinical features including menstrual irregularities and hirsutism are usually not apparent until middle to late adolescence. Yet studies suggest that PCOS may begin in early puberty. Young women with premature pubarche, a family history of PCOS, Caribbean Hispanic and African American ancestry, and/or obesity are more likely to develop PCOS. Adolescents with PCOS may have elevated total or free testosterone, androstenedione, and luteinizing hormone levels; insulin resistance; and hyperinsulinemia. The laboratory evaluation and management of the adolescent with suspected PCOS should be individualized on the basis of the clinical features and symptoms. The cornerstone of most treatment strategies includes either a combination oral contraceptive or progestin to decrease testosterone levels and regulate the menstrual cycle. Consideration of insulin-sensitizing agents, antiandrogens, topical treatments for acne and excess facial hair, and hair removal is dependent on the patient's symptoms and concerns. A healthy approach to eating, in some cases weight loss, and exercise is encouraged to reduce the risk of cardiovascular disease and type 2 diabetes mellitus. Management of the adolescent with PCOS is challenging and often requires a supportive, multidisciplinary team approach for optimal results.

REFERENCES

  • 1 Michelmore K F, Balen A H, Dunger D B, Vessey M P. Polycystic ovaries and associated clinical and biochemical features in young women.  Clin Endocrinol (Oxf) . 1999;  51 779-786
  • 2 Avvad C K, Holeuwerger R, Silva V C, Bordallo M A, Breitenbach M M. Menstrual irregularity in he first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence.  Gynecol Endocrinol . 2001;  15 170-177
  • 3 Rosenfield R L, Ghai K, Ehrmann D A, Barnes R B. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism.  J Pediatr Endocrinol Metab . 2000;  13 1285-1289
  • 4 Ibanez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence.  J Clin Endocrinol Metab . 1999;  84 2691-2695
  • 5 Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.  J Dermatol . 1997;  24 223-229
  • 6 Slayden S M, Moran C, Sams Jr M W, Boots L R, Azziz R. Hyperandrogenemia in patients presenting with acne.  Fertil Steril . 2001;  75 889-892
  • 7 Plouffe Jr L. Disorders of excessive hair growth in the adolescent.  Obstet Gynecol Clin North Am . 2000;  27 79-99
  • 8 van Hooff H A M, Voorhorst F J, Kaptein M BH, Hirasing R A, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents.  Hum Reprod . 1999;  14 2223-2229
  • 9 DiMartino-Nardi J. Pre- and postpubertal findings in premature adrenarche.  J Pediatr Endocrinol Metab . 2000;  13 1265-1269
  • 10 Arslanian S A. Type 2 diabetes mellitus in children: pathophysiology and risk factors.  J Pediatr Endocrinol Metab . 2000;  13 1385-1394
  • 11 van Hooff H A M, Voorhorst F J, Kaptein M BH, Hirasing R A, Koppenaal C, Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin.  Fertil Steril . 2000;  74 49-58
  • 12 Ibanez L, Potau N, Virdis R. et al . Post-pubertal outcome in girls diagnosed of premature pubarche during childhood: increased incidence of functional ovarian hyperandrogenism.  J Clin Endocrinol Metab . 1993;  76 1599-1603
  • 13 Ibanez L, DiMartino-Nardi J, Potau N, Saenger P. Premature adrenarche: normal variant or forerunner of adult disease.  Endocrine Rev . 2000;  21 671-696
  • 14 Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism risk in girls: relation to reduced fetal growth.  J Clin Endocrinol Metab . 1998;  83 3558-3662
  • 15 Ibanez L, Potau N, Dunger D, de Zegher F. Precocious pubarche in girls and the development of androgen excess.  J Pediatr Endocrinol Metab . 2000;  13 1261-1263
  • 16 Ibanez L, Castell C, Tresserras R, Potau N. Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche.  Clin Endocrinol (Oxf) . 1999;  51 395-401
  • 17 Slyper A H. Childhood obesity, adipose tissue distribution, and the pediatric practitioner.  Pediatrics . 1998;  102 1-9
  • 18 Legro R S, Driscoll D, Strauss III F J, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.  Proc Natl Acad Sci U S A . 1998;  95 14956-14960
  • 19 Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.  Fertil Steril . 2001;  75 53-58
  • 20 Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor 1 hypothesis.  Fertil Steril . 1992;  56 655-666
  • 21 Veldhuis J D, Pincus S M, Garcia-Rudaz M C, Ropelato M G, Escobar M E, Barontini M. Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome.  J Clin Endocrinol Metab . 2001;  86 72-79
  • 22 Taylor A E. The gonadotropic axis in hyperandrogenic adolescents.  J Pediatr Endocrinol Metab . 2000;  13 1281-1284
  • 23 Garica-Rudaz M C, Ropelato M, Escobar M E, Veldhuis J D, Bartontini M. Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome.  Eur J Endocrinol . 1998;  139 621-630
  • 24 Pugeat M, Cousin P, Baret C, Lejeune H, Forest M G. Sex hormone-binding globulin during puberty in normal and hyperandrogenic girls.  J Pediatr Endocrinol Metab . 2000;  13 1277-1279
  • 25 Libman I, Arslanian S A. Type II diabetes mellitus: no longer just adults.  Pediatr Ann . 1999;  28 589-593
  • 26 American Diabetes Association. Consensus conference on type 2 diabetes in children.  Diabetes Care . 2000;  23 381-389
  • 27 Apter D, Butzow T, Laughlin G A, Yen S S. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.  J Pediatr Endocrinol Metab . 1995;  80 2966-2973
  • 28 Lewy V D, Danadian K, Witychel S F, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome.  J Pediatr . 2001;  138 38-44
  • 29 American Society for Reproductive Medicine. Technical Bulletin: The Evaluation and Treatment of Androgen Excess. Birmingham, AL: ASRM; April 2000
  • 30 Rosenfield R L, Cara J F. Androgens and the adolescent girl. In: Sanfilippo JS, Muram D, Dewhurst J, Lee PA, eds. Pediatric and Adolescent Gynecology Philadelphia: WB Saunders; 2001: 269-294
  • 31 Azziz R. The time has come to simplify the evaluation of the hirsute patient.  Fertil Steril . 2000;  74 870-872
  • 32 McKenna T J. Screening for sinister causes of hirsutism.  N Engl J Med . 1994;  331 1015-1016
  • 33 Azziz R. Demystifying fallacies surrounding nonclassic adrenal hyperplasia.  Contemp Ob/Gyn . 1996;  5 109-113
  • 34 Jamieson M A, Reid R L. Opinions in pediatric and adolescent gynecology.  J Pediatr Adolesc Gynecol . 2001;  14 95-97
  • 35 Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1998;  83 2694-2698
  • 36 Vuguin P, Saenger P, DiMartino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche.  Pediatr Res . 1999;  45 99A
  • 37 Gordon C M. Menstrual disorders in adolescents: excess androgens and the polycystic ovary syndrome.  Pediatr Clin North Am . 1999;  46 519-543
  • 38 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.  Endocr Rev . 1997;  18 774-800
  • 39 Burkman R T. The role of oral contraceptives in the treatment of hyperandrogenic disorders.  Am J Med . 1995;  98 1305-1365
  • 40 Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives.  Semin Reprod Endocrinol . 1989;  7 246-254
  • 41 The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer.  JAMA . 1987;  257 796-800
  • 42 Balfour J A, McClellan K. Topical eflornithine.  Am J Clin Dermatol . 2001;  2 197-201
  • 43 Redmond G P, Olson W H, Lippman J S. et al . Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo controlled trial.  Obstet Gynecol . 1997;  89 615-622
  • 44 Hoeger K. Obesity and weight loss in polycystic ovary syndrome.  Obstet Gynecol Clin North Am . 2001;  28 85-97
  • 45 Bates G W, Whitworth N S. Effect of body weight reduction on plasma androgens in obese, infertile women.  Fertil Steril . 1982;  38 406-409
  • 46 Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome.  Hum Reprod . 1997;  12 82-87
  • 47 Kiddy D S, Hamilton-Fairley D, Bush A. et al . Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf) . 1992;  36 105-111
  • 48 Huber-Buchholz M M, Carey D GP, Norman R J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.  J Clin Endocrinol Metab . 1999;  84 1470-1474
  • 49 Michelmore K F, Balen A H, Dunger D B. Polycystic ovaries and eating disorders: are they related?.  Hum Reprod . 2001;  16 765-769
  • 50 AHA/ACC Scientific Statement. Consensus Panel Statement Guide to Preventative Cardiology for Women.   Circulation . 1999;  99 2480-2484
  • 51 Oberfield S E. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome: is insulin, indeed, the culprit?.  <~>[editorial]. J Clin Endocrinol Metab . 2000;  85 3520-3525
  • 52 Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).  J Adolesc Health . 2001;  29 160-169
  • 53 Ibanez L, Valls C, Potau N, Marcos M V, De Zehger F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinemia after precocious pubarche.  J Clin Endocrinol Metab . 2000;  85 3526-3530
  • 54 Trent M, Rich M, Austin S B, Gordon C. Polycystic ovary syndrome in adolescent girls: fertility concerns and sexual behavior.  J Pediatr Adolesc Gynecol . 2001;  14 144-146